KZR
Kezar Life Sciences, Inc.
Key Financials
Revenue
$0
NaN%
Net Income
$-56033000
↑ 33.1%
Operating Income
$-59107000
↑ 34.8%
Total Assets
$76.6M
↓ 47.0%
EPS (Diluted)
$-7.66
↑ 33.3%
Total Liabilities
$6.6M
↓ 76.3%
Shareholders' Equity
$70.1M
↓ 40.1%
Cash & Equivalents
$71.9M
↑ 72.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/28/2026 | View on SEC |
| 15-12G | 5/21/2026 | View on SEC |
| EFFECT | 5/14/2026 | View on SEC |
| SCHEDULE 13D/A | 5/13/2026 | View on SEC |
| SCHEDULE 13G/A | 5/12/2026 | View on SEC |
| SCHEDULE 13G/A | 5/12/2026 | View on SEC |
| 4 | 5/11/2026 | View on SEC |
| 4 | 5/11/2026 | View on SEC |
| 4 | 5/11/2026 | View on SEC |
| 4 | 5/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KZR |
| Company Name | Kezar Life Sciences, Inc. |
| CIK | 1645666 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-822-5600 |